News and Events
Assessing genetic heterogeneity in circulating tumour cells to improve treatments
Researchers around Niko Beerenwinkel, head of the Computational Biology group, in collaboration with the group of Nicola Aceto from the ETH-Department of Biology, are studying genetic heterogeneity in clusters of cancer cells travelling through the blood to seed new tumours in the body. Their study in Nature Genetics characterises the composition of these circulating tumour cell clusters in liquid biopsies which may eventually replace traditional tissue biopsies in the medical practice.
Study demonstrates benefits of molecular tumour analysis
Every tumour is unique. This makes it difficult to find the most effective therapy for treatment. Researchers in Zurich and Basel are now showing how state-of-the-art molecular biological technologies can be used to create a detailed tumour profile within four weeks, enabling tailored treatment. The study is the first of its kind in the world.
Congratulations to our 2024 Graduates!
On 23 May, 24 Biotechnology and 27 Computational Biology & Bioinformatics graduates attended the D-BSSE graduation ceremony together with their families and friends, in total some 180 guests. We are especially pleased to have two ETH medallists and three Willi Studer Prize awardees this year. Huge congratulations to all our graduates and best of success for a bright future!
ETH Medal for excellent research: cell-cell interactions | CRISPR screening technology
Costanza Borrelli who studied cell-cell interactions during her doctorate in the Moor Lab, and Antonio Jose da Silva Santinha from the Platt Lab, inventor of a novel technology for single-cell CRISPR screening, received the 2024 ETH Medals for their doctoral theses. Big congratulations!
Mapping the future of organoids
Scientists from Roche's Institute of Human Biology, their partners at ETH Zurich and Helmholtz Munich, and collaborators have built detailed atlases of brain, gut, and lung organoids to empower future discovery.
Welcoming the public to a fascinating journey into the microscopic and nanoscopic worlds
On 6 May, the Single Cell and Lab Automation Facilities opened their doors to learn about the secrets of life. After a short introduction by Thomas Horn, Head of the facilities, on how tiny details in cells are visualised using state-of-the-art laser microscopes, the visitors to the fully booked tour saw some of the top-notch instruments and gained stunning insights to microscopy and lab robotics.
Upcoming Public Tour: Microscopy and Lab Robotics on 6 May
On 6 May, D-BSSE again opens a lab to the public: On this guided tour through the Single Cell and Lab Automation Facility you will see how tiny details in cells are visualised using state-of-the-art laser microscopes. By immersing ourselves in the fascinating world of the microcosm, we can unlock the secrets of life. We will also show you how automation is finding its way into the laboratory. Registration is open now!
SNSF Consolidator Grant for Prisca Liberali
Congratulations to Prisca Liberali, head of the Multicellular Systems Lab, on receiving the Consolidator Grant of the Swiss National Science Foundation for her research on the self-organisation of multi-cellular systems.
Public lecture on liver metastases
As part of a public event series organised by Treffpunkt Science City, Andreas Moor, head of the Systems Physiology Lab, gave a lecture on liver metastases. Researchers recently discovered how bowel cancer cells dock onto the liver: they detach from the initial tumour, enter the bloodstream and settle in the capillary network of the liver. However, the tumour cells need the support of liver cells to grow into metastases. This finding could enable new therapies to prevent tumour metastases.
New deep-learning based tool capturing combinatorial mutations in SARS-CoV-2
The emergence of SARS-CoV-2 variants such as Beta, Gamma, Delta and Omicron is a critical factor for drug development. Researchers around Sai Reddy, head of the Synthetic Immunology lab, now present a computational tool that enables the selection and focused development of lead candidates of antibodies that have the most potential to maintain activity against a rapidly mutating SARS-CoV-2. The deep learning-guided approach identifies antibodies with enhanced resistance to the evolving virus.